The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von G Wójcicka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: grazyna.wojcicka@umlub.p…. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Metabolic Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: Uniwersytet Medyczny w Lublinie.
Abstract (Originalsprache)
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis. We aimed to investigate whether the cardioprotective and antifibrotic effects of incretin drugs, exenatide and sitagliptin, may be associated with their ability to affect circulating and cardiac ADMA metabolism. Normal and fructose-fed rats were treated with sitagliptin (5.0/10 mg/kg) or exenatide (5/10 µg/kg) for 4 weeks. The following methods were used: LC-MS/MS, ELISA, Real-Time-PCR, colorimetry, IHC and H&E staining, PCA and OPLS-DA projections. Eight-week fructose feeding resulted in an increase in plasma ADMA and a decrease in NO concentration. Exenatide administration into fructose-fed rats reduced the plasma ADMA level and increased NO level. In the heart of these animals exenatide administration increased NO and PRMT1 level, reduced TGF-ß1, α-SMA levels and COL1A1 expression. In the exenatide treated rats renal DDAH activity positively correlated with plasma NO level and negatively with plasma ADMA level and cardiac α-SMA concentration. Sitagliptin treatment of fructose-fed rats increased plasma NO concentration, reduced circulating SDMA level, increased renal DDAH activity and reduced myocardial DDAH activity. Both drugs attenuated the myocardial immunoexpression of Smad2/3/P and perivascular fibrosis. In the metabolic syndrome condition both sitagliptin and exenatide positively modulated cardiac fibrotic remodeling and circulating level of endogenous NOS inhibitors but had no effects on ADMA levels in the myocardium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: grazyna.wojcicka@umlub.pl.
- Department of Pathophysiology, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: anna.pradiuch@umlub.pl.
- Department of Bioanalytic, Medical University of Lublin ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: emilia.fornal@umlub.pl.
- Department of Bioanalytic, Medical University of Lublin ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: anna.stachniuk@umlub.pl.
- Department of Clinical Pathology, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: agnieszka.korolczuk@umlub.pl.
- Department of Clinical Pathology, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Electronic address: barbara.marzec-kotarska@umlub.pl.
Förderung
- Uniwersytet Medyczny w Lublinie
Zitieren
APA
Wójcicka, G., Pradiuch, A., Fornal, E., Stachniuk, A., Korolczuk, A., Marzec-Kotarska, B., Nikolaichuk, H., Czechowska, G., Kozub, A., Trzpil, A., Góralczyk, A., & Bełtowski, J. (2023). The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115637
Vancouver
Wójcicka G, Pradiuch A, Fornal E, Stachniuk A, Korolczuk A, Marzec-Kotarska B, et al. The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115637
BibTeX
@article{Wjcicka2023,
author = {Wójcicka, G and Pradiuch, A and Fornal, E and Stachniuk, A and Korolczuk, A and Marzec-Kotarska, B and Nikolaichuk, H and Czechowska, G and Kozub, A and Trzpil, A and Góralczyk, A and Bełtowski, J},
title = {The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115637}
}
EUVIMED